[go: up one dir, main page]

WO2004077942A3 - Inducible prostate cancer model - Google Patents

Inducible prostate cancer model Download PDF

Info

Publication number
WO2004077942A3
WO2004077942A3 PCT/US2004/006118 US2004006118W WO2004077942A3 WO 2004077942 A3 WO2004077942 A3 WO 2004077942A3 US 2004006118 W US2004006118 W US 2004006118W WO 2004077942 A3 WO2004077942 A3 WO 2004077942A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
inducible
cancer model
mammal
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006118
Other languages
French (fr)
Other versions
WO2004077942A2 (en
Inventor
Joerg Heyer
Lynda Chin
Ronald A Depinho
Scott Alson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Genpath Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpath Pharmaceuticals Inc filed Critical Genpath Pharmaceuticals Inc
Publication of WO2004077942A2 publication Critical patent/WO2004077942A2/en
Publication of WO2004077942A3 publication Critical patent/WO2004077942A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to non-human mammals and cells comprising an expression construct for a nucleic acid encoding a prostate cancer related oncogene and wherein the mammal and cell further comprises a cancer-prone genetic predisposition.
PCT/US2004/006118 2003-02-28 2004-02-27 Inducible prostate cancer model Ceased WO2004077942A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45133103P 2003-02-28 2003-02-28
US60/451,331 2003-02-28

Publications (2)

Publication Number Publication Date
WO2004077942A2 WO2004077942A2 (en) 2004-09-16
WO2004077942A3 true WO2004077942A3 (en) 2005-05-12

Family

ID=32962581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006118 Ceased WO2004077942A2 (en) 2003-02-28 2004-02-27 Inducible prostate cancer model

Country Status (1)

Country Link
WO (1) WO2004077942A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338883B (en) 2010-07-27 2016-05-04 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009308A1 (en) * 1999-07-29 2001-02-08 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
WO2002079419A2 (en) * 2001-03-28 2002-10-10 Dana-Farber Cancer Institute, Inc. Identifying and characterizing genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009308A1 (en) * 1999-07-29 2001-02-08 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
WO2002079419A2 (en) * 2001-03-28 2002-10-10 Dana-Farber Cancer Institute, Inc. Identifying and characterizing genes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABATE-SHEN C ET AL: "Mouse models of prostate carcinogenesis", TRENDS IN GENETICS, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 5, 1 May 2002 (2002-05-01), pages S1 - S5, XP004359981, ISSN: 0168-9525 *
CASTRILLON D H ET AL: "Modeling prostate cancer in the mouse.", ADVANCES IN CANCER RESEARCH. 2001, vol. 82, 2001, pages 187 - 204, XP009035874, ISSN: 0065-230X *
CHIN L ET AL: "FLIPPING THE ONCOGENE SWITCH ILLUMINATION OF TUMOR MAINTENANCE AND REGRESSION", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 16, no. 4, April 2000 (2000-04-01), pages 147 - 150, XP002924262, ISSN: 0168-9525 *
GUNTHER EDWARD J ET AL: "Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 17, no. 4, 15 February 2003 (2003-02-15), pages 488 - 501, XP002289590, ISSN: 0890-9369 *
HUSS WENDY J ET AL: "Autochthonous mouse models for prostate cancer: Past, present and future", SEMINARS IN CANCER BIOLOGY, vol. 11, no. 3, June 2001 (2001-06-01), pages 245 - 259, XP002294564, ISSN: 1044-579X *
STEINER MITCHELL S ET AL: "Antisense c-myc retroviral vector suppresses established human prostate cancer", HUMAN GENE THERAPY, vol. 9, no. 5, 20 March 1998 (1998-03-20), pages 747 - 755, XP009035908, ISSN: 1043-0342 *
WANG HUI ET AL: "Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms.", PROSTATE, vol. 54, no. 3, 15 February 2003 (2003-02-15), pages 194 - 205, XP009035903, ISSN: 0270-4137 *
WANG YUZHUO ET AL: "Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue", CANCER RESEARCH, vol. 60, no. 21, 1 November 2000 (2000-11-01), pages 6008 - 6017, XP002295156, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2004077942A2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
AU2003293169A1 (en) Corrosion resistant pem fuel cell
EP1667265A4 (en) Membrane-electrode assembly for solid polymer fuel cell
AU2003211122A1 (en) Simplified direct oxidation fuel cell system
AU2002351280A1 (en) Composite electrolyte for fuel cells
AU2003253738A1 (en) Degasified pem fuel cell system
AU2002216859A1 (en) Compression mechanism for an electrochemical fuel cell assembly
DE69835145D1 (en) Transgenic mice expressing a human antibody
DE112004001465B8 (en) Fuel cell vehicle
WO2006069339A8 (en) Genetic variants of vkorci predicting warfarin sensitivity
WO2002079419A3 (en) Identifying and characterizing genes
GB0411735D0 (en) Fuel cell system
AU2003217382A8 (en) Fuel cell electrocatalyst of pt-rh-mo-ni/fe
AU2003207344A1 (en) Electrochemical cell for metal production
WO2007002664A3 (en) Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
WO2004077942A3 (en) Inducible prostate cancer model
WO2004089073A3 (en) Inducible breast cancer model
WO2007012811A3 (en) Prostate stem cell markers
WO2005017127A3 (en) Rna interference compositions and methods
IL165984A0 (en) Transgenic non-huammal cells isolated therefrom and an isolated nucleic acid construct
DE60212503D1 (en) Liquid distribution surfaces for solid electrolyte fuel cells
SG95698A1 (en) Dna for encoding d-hydantoin hydrolases, dna for encoding n-carbamyl-d-amino acid hydrolases, recombinant dna containing the genes, cells transformed with the recombinant dna, methods for producing pr
GB2409925B (en) Fuel cell system
WO2003004616A3 (en) Dendritic cell isolation methods
ZA200704058B (en) Methods for producing mammalian cells
WO1999028453A3 (en) Transgenic non-human mammals with an oncogenic mutant of raf gene 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase